Latest News

Whitehaven Coal (ASX:WHC) is back in focus after the board approved a new on market share buyback of up to A$32 million, alongside a reduced A$0.04 dividend for the half year. See our latest analysis for Whitehaven Coal. The new on market buyback and lower dividend come after a mixed stretch for the shares, with a 1 day share price return of 1.66% and a 90 day share price return of 11.52%, set against a 10.08% decline over 30 days and a very large 5 year total shareholder return. Taken...

Waypoint REIT recently reported its full-year 2025 results, with sales of A$162.6 million, net income of A$200.1 million, and higher earnings per share despite slightly lower revenue than the prior year. The results highlighted resilient rental income, a 1% uplift in distributable earnings per security, a completed A$50 million buyback below net tangible asset value, and long-term lease extensions with major tenant Viva Energy Australia that are set to increase aggregate rent from August...

In recent weeks, Olema Pharmaceuticals announced the departure of its COO and CFO, Shane Kovacs, who will remain as a consultant through August 1, 2026, while CEO Sean Bohen temporarily assumes principal financial officer responsibilities. At the same time, continued Buy ratings from Citi and new coverage from Stifel have put a spotlight on palazestrant’s commercial potential in the sizeable endocrine therapy market and growing hedge fund interest in the stock. With this context, we’ll...

In late February 2026, NovoCure reported fourth-quarter 2025 revenue of US$174.35 million and a quarterly loss of US$24.5 million, alongside full-year 2025 revenue of US$655.35 million and a narrowed annual loss of US$136.23 million, while issuing 2026 net revenue guidance of US$675 million to US$705 million. Alongside these results, NovoCure secured U.S. FDA approval and began the commercial launch of Optune Pax for locally advanced pancreatic cancer, signaling a shift from a...

In recent months, Scorpio Tankers reported strong fourth-quarter results, with net income rising to US$128.1 million and daily TCE rates increasing year over year, while shifting its balance sheet from US$3.10 billions in net debt in 2021 to roughly US$334 million in net cash by early 2026. The company complemented this financial improvement with a higher quarterly dividend of US$0.45 per share and continued investment in scrubber-fitted vessels, pointing to a focus on cash returns and...

Turan Drilling and Engineering Company LLC, the joint venture between Helmerich & Payne and bp, recently secured a renewed offshore operations and maintenance contract from bp in the Caspian Sea, offshore Azerbaijan, with a firm 5-year term and three optional 1-year extensions that together could exceed US$1.00 billion in value. This long-term renewal underscores how Helmerich & Payne’s partnership role with bp in the Caspian Sea may support more predictable revenue and operational...

In late February 2026, CCL Industries Inc. reported 2025 results showing higher annual sales of CA$7,663.8 million, lower annual net income of CA$802.4 million, and raised its quarterly dividend by 12.5% to CA$0.36 per share while expanding its share repurchase authorizations, including an automatic securities purchase plan. This combination of record top-line performance, increased cash returns via dividends and buybacks, and the ability to repurchase shares even during blackout periods...

Preferred Bank (PFBC) has drawn fresh attention after recent trading left the stock around $87.72. Mixed returns over the past week, month and past 3 months are prompting investors to reassess its current valuation. See our latest analysis for Preferred Bank. The recent 1 day share price decline of 3.36% and year to date share price return of negative 8.57% contrast with a 1 year total shareholder return of 3.12%. This suggests shorter term momentum has cooled even as longer term holders have...

Recent broker updates on New World Development (SEHK:17) have drawn attention to its debt optimization efforts and expectations for a return to positive operating cash flow, shifting investor focus toward balance sheet repair and cash generation. See our latest analysis for New World Development. The recent broker updates sit against a mixed share price picture, with a 47.81% 3 month share price return and 36.81% year to date gain, contrasting with a 1 month share price decline of 11.16% and...

Dyne Therapeutics, Inc. reported a full-year 2025 net loss of US$446.21 million, with basic and diluted loss per share from continuing operations of US$3.47, and also filed a US$128.83 million shelf registration for 8,247,527 common shares related to its employee stock ownership plans. Amid this widening loss, Dyne is progressing its neuromuscular pipeline, including plans to seek U.S. Accelerated Approval for z-rostudirsen in Duchenne muscular dystrophy, which highlights how funding moves...

Madison Square Garden Entertainment Corp. recently disclosed that a data breach discovered on or about December 16, 2025 exposed personal information via a vulnerability in Oracle’s eBusiness Suite, prompting legal investigations by Edelson Lechtzin LLP on behalf of affected individuals. Beyond potential legal and remediation costs, this incident puts the company’s data security and operational controls under scrutiny at a time when it relies heavily on customer trust for its live...

Silver Storm Mining Ltd. recently reported a wider quarterly net loss of C$2.43 million and provided a detailed progress update on rehabilitating its 100%-owned La Parrilla processing plant in Durango, Mexico, including advances in crushing, flotation, milling, and oxide leach circuits. A key takeaway is the planned increase in nominal sulphide flotation capacity from 1,000 to 1,250 tonnes per day once new cells and refurbishments are completed, signalling a clearer path toward enhanced...

F&G Annuities & Life, Inc. and Voya Financial, Inc. previously announced that F&G’s annuity solutions would be distributed through Voya’s Wealth Management platform, giving Voya financial professionals access to F&G products, education and support for retirement and income protection planning. This collaboration combines F&G’s product range with Voya’s advisory reach, potentially broadening F&G’s presence in the US retirement market and deepening advisor adoption of its annuity...

Relay Therapeutics, Inc. recently reported full-year 2025 results, with revenue rising to US$15.36 million from US$10.01 million and its net loss narrowing to US$276.48 million from US$337.71 million, while also securing FDA Breakthrough Therapy designation and advancing multiple 2026 data milestones for lead asset zovegalisib. Alongside a narrower basic loss per share of US$1.61 versus US$2.36 a year earlier, the company filed a US$96.18 million common-stock shelf registration tied to an...

Astec Industries, Inc. has now reported its fourth-quarter and full-year 2025 results, with Q4 sales rising to US$400.6 million from US$359.0 million and full-year sales reaching US$1.41 billion, while net income increased to US$38.8 million for 2025 and the Board maintained a quarterly dividend of US$0.13 per share payable in March 2026. Despite Q4 net income easing year on year, the company delivered record quarterly and annual sales, beat analyst earnings and revenue expectations,...

Public Property Invest (OB:PUBLI) shares are in focus after the company released its fourth quarter and full year 2025 results, highlighting higher revenue alongside mixed net income trends across the quarter and the full year. See our latest analysis for Public Property Invest. At a share price of NOK23.3, Public Property Invest has delivered a 6.64% 90 day share price return and a 29.38% 1 year total shareholder return. This indicates that momentum has been positive as the market digests...

NICE (TASE:NICE) just paired strong fourth quarter and full year 2025 earnings with fresh 2026 growth guidance and a new share repurchase plan, putting its cloud and AI businesses in clear focus for investors. See our latest analysis for NICE. Despite the latest earnings beat, NICE’s 1-year total shareholder return of about a 30% decline and 3-year total shareholder return of roughly a 54% decline contrast with a recent 7.22% 30-day share price return and new buyback activity. This suggests...

IMAX Corporation recently reported fourth-quarter 2025 revenue of US$125.21 million and full-year 2025 revenue of US$410.21 million, with annual net income rising to US$34.88 million even as quarterly net income softened. The company paired these record box office and revenue results with ongoing global network expansion and deeper local-language and live-event content partnerships, including a new collaboration with Apple TV to screen select 2026 Formula One races in IMAX theaters. We’ll...

What Pfizer’s Recent Share Performance Signals for Investors With no single headline event driving the move, Pfizer (PFE) has quietly posted positive returns over the past week, month, and past 3 months. This naturally raises questions about what is being priced into the stock. See our latest analysis for Pfizer. At a share price of $27.65, Pfizer’s recent 1 day share price return of 2.03%, 30 day share price return of 4.58%, and roughly 10% year to date share price return suggest momentum...

Chemed Corporation recently reported fourth-quarter 2025 results showing net income of US$76.75 million and full-year 2025 net income of US$265.24 million, both lower than the prior year, alongside 2026 adjusted earnings guidance of US$23.25–US$24.25 per diluted share. Despite ongoing share repurchases totaling US$2.62 billion since 2011, investors focused on pressure in VITAS and Roto-Rooter margins, including Medicare Cap constraints and water-restoration write-offs. We’ll now examine how...

In February 2026, Guardant Health reported fourth-quarter 2025 revenue of US$281.27 million and a net loss of US$128.49 million, filed a US$510.17 million shelf registration for 4,795,700 common shares tied to employee stock plans, and issued 2026 revenue guidance of US$1.25–1.28 billion. Alongside these filings and results, Guardant’s inclusion as a leading contributor in an institutional growth fund and commentary about volume-driven expansion and acquisition activity highlighted growing...

Jehoshaphat Research’s short report on GPGI (GPGI), centered on alleged overstatement of Husky Technologies’ financial metrics and the abrupt CEO and CFO resignations, has quickly become a key focus for traders assessing the stock. See our latest analysis for GPGI. GPGI’s latest short report comes after a year where the share price has moved sharply at times, with a 20.25% year to date share price return and a very large 3 year total shareholder return of about 4x. This is even with a recent...

Traton (XTRA:8TRA) shares are back in focus after the company extended the contract of key executive Antonio Roberto Cortes, a leadership decision that may influence future operations and long-term planning. See our latest analysis for Traton. At a share price of €36.04, Traton has seen a 9.41% 1 month share price return and 26.10% 3 month share price return. The 3 year total shareholder return of 144.24% and 5 year total shareholder return of 68.69% point to stronger longer term momentum...

In late February 2026, Mirum Pharmaceuticals reported Q4 2025 revenue of US$148.93 million and a quarterly net loss of US$5.73 million, alongside filing shelf registrations to potentially issue up to 12,074,780 new common shares worth about US$1.30 billion. While these results showed a smaller annual net loss of US$23.36 million on full-year revenue of US$521.31 million, the large prospective equity issuance raised fresh questions about dilution and how Mirum plans to finance its ongoing...